SMB00387
Prothionamide
≥99% (HPLC)
别名:
Prothionamide, 2-propyl-4-pyridinecarbothioamide, 2-propylisonicotinylthioamide, 2-propylthioisonicotinamide, 2-Propyl-4-pyridinecarbothioamide, 2-Propylisonicotinylthioamide
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C9H12N2S
化学文摘社编号:
分子量:
180.27
NACRES:
NA.85
PubChem Substance ID:
UNSPSC Code:
51102829
MDL number:
Quality Level
assay
≥99% (HPLC)
form
powder
color
yellow
antibiotic activity spectrum
mycobacteria
mode of action
enzyme | interferes
storage temp.
−20°C
SMILES string
NC(C1=CC(CCC)=NC=C1)=S
InChI
1S/C9H12N2S/c1-2-3-8-6-7(9(10)12)4-5-11-8/h4-6H,2-3H2,1H3,(H2,10,12)
InChI key
VRDIULHPQTYCLN-UHFFFAOYSA-N
General description
Chemical structure: pyridine
Prothionamide is an analogue of ethionamide, and is better tolerated and less toxic than ethionamide. It contains a propyl group instead of an ethyl group at the α position.
Biochem/physiol Actions
Prothionamide is the second line of drug used in leprosy and in tuberculosis. It is highly effective against Mycobacterium tuberculosis. In patients with multidrug-resistant tuberculosis (MDR-TB), prothionamide causes the development of hepatitis. In rare cases, it causes drug reaction with eosinophilia and systemic symptoms (DRESS) in patients with MDR-TB. DRESS is characterized by fever, hematologic abnormalities, skin eruption, and internal organ disruption.
Preparation Note
Keep container tightly closed in a dry and well-ventilated place. Storage class (TRGS 510) Non Combustible liquids.
Other Notes
Keep container tightly closed in a dry and well-ventilated place. Storage class (TRGS 510): Non Combustible Solids
A Yilmaz et al.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 152, 262-271 (2015-07-29)
Prothionamide (PTH) is the secondary drug used against Mycobacterium tuberculosis bacteria and leprosy. The aim of this work was to investigate the potential energy surface map, anharmonic and harmonic vibrational spectra, NBO analysis and ELF (Electron Localization Function) of the
Han-Lin Hsu et al.
Journal of the Formosan Medical Association = Taiwan yi zhi, 109(12), 923-927 (2011-01-05)
Timely and intensive monitoring for, and management of, adverse effects caused by anti-tuberculosis drugs are essential components of control programs for multidrug-resistant tuberculosis (MDR-TB). This retrospective case series was conducted in northern Taiwan from January 2007 to December 2008 at
Acceptability of thioamides. II. Prothionamide.
D K Gupta
Journal of postgraduate medicine, 23(4), 181-185 (1977-10-01)
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SMB00387-1G | 04061826650905 |
| SMB00387-10G | 04061832992365 |